Novo Nordisk v. Lupin: Victoza Liraglutide Patent Case Transferred to Camden
Novo Nordisk, Inc. and Novo Nordisk A/S brought a patent infringement action against Indian generic manufacturer Lupin, Ltd. in the District of New Jersey, asserting US8114833B2 covering their Victoza liraglutide injection product. After 169 days, the case was transferred to the Camden Division and renumbered 1:23-cv-4027.
Liraglutide patent dispute reassigned within New Jersey federal courts
On 27 July 2023, Novo Nordisk, Inc. and its Danish parent Novo Nordisk A/S filed suit against Lupin, Ltd. in the United States District Court for the District of New Jersey, asserting infringement of US8114833B2. The patent relates to Victoza, Novo Nordisk’s branded liraglutide recombinant solution for injection at 18 mg/3 ml (6 mg/ml), a GLP-1 receptor agonist used in the treatment of type 2 diabetes. The action is consistent with ANDA-related Hatch-Waxman litigation, whereby a brand manufacturer seeks to block a generic entrant from launching before patent expiry.
On 12 January 2024, after 169 days of proceedings in the Newark docket, the court ordered the case transferred to the Camden Division of the same district. The case was reassigned the new docket number 1:23-cv-4027. A transfer within the same district does not constitute a dismissal or a substantive ruling on the merits; the litigation continues under a different divisional assignment, before a Camden-based judge, with all pleadings and filings carried over.
The relatively swift transfer — within the same federal district — suggests an administrative or judicial assignment reason rather than a forum dispute between the parties. No merits ruling, claim construction order, or settlement has been recorded in the public docket under the original case number. The underlying infringement dispute over US8114833B2 and Lupin’s proposed generic liraglutide product therefore remains unresolved from the public record, continuing before the Camden Division.
Filing to resolution in 169 days
169 days before intra-district transfer to Camden Division
What the intra-district transfer means for this litigation
Intra-district transfer: the litigation is still live
A transfer to the Camden Division of the District of New Jersey is an administrative reassignment within the same federal court system. It is not a dismissal, a judgment, or a settlement. All claims, patents asserted, and parties remain unchanged. The case continues under docket number 1:23-cv-4027 before a Camden-seated judge. No substantive rights of either party are affected by the transfer order itself.
Case still active post-transferCamden vs. Newark: what changes for the parties
Within the District of New Jersey, Newark and Camden divisions operate under the same Local Patent Rules but may be assigned to different judges with distinct scheduling practices and case management styles. Parties should verify the assigned judge in the Camden docket and review their individual standing orders. Procedural timelines — including claim construction schedules and discovery deadlines — may be reset or revised by the transferee judge.
Same rules, different judgeWhy generic drug patent cases are commonly reassigned
District of New Jersey is one of the busiest Hatch-Waxman jurisdictions in the United States. Intra-district transfers in pharmaceutical patent cases frequently reflect judicial workload balancing or case-related consolidation with related ANDA litigation. It is common for multiple Hatch-Waxman cases involving the same drug to be coordinated before a single judge, which may explain the Camden reassignment here.
NJ Hatch-Waxman practiceTrack the Camden docket for substantive developments
Stakeholders and competitors should monitor docket 1:23-cv-4027 in the Camden Division for claim construction briefing, any IPR filings against US8114833B2, and settlement signals. The 30-month stay under Hatch-Waxman — triggered when a brand sues a generic within 45 days of paragraph IV certification — may govern Lupin’s ability to launch. Tracking the stay expiry date is commercially critical for all parties in the liraglutide market.
Monitor 1:23-cv-4027Full party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Novo Nordisk, Inc. | Company | Global pharmaceutical innovator — holder of US8114833B2 covering Victoza liraglutide injectionSearch in Eureka ↗ |
| Defendant | Lupin, Ltd. | Company | Lupin, Ltd. — India-based multinational generic pharmaceutical manufacturerSearch in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for Novo Nordisk, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Charles Michael Lizza | Attorney | Counsel for Novo Nordisk, Inc.Search in Eureka ↗ |
| Plaintiff counsel | David Feder | Attorney | Counsel for Novo Nordisk, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Sarah Ann Sullvian | Attorney | Counsel for Novo Nordisk, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for Novo Nordisk, Inc.Search in Eureka ↗ |
| Defendant counsel | James S. Richter | Attorney | Counsel for Lupin, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge / | Chief Judge | New Jersey District Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The transfer order — ‘Case transferred to Camden Division on 1/12/2024. New Case Number 1:23-cv-4027’ — is a purely procedural disposition with no substantive legal effect on either party’s claims or defences. It confirms the litigation is ongoing and carries over all prior pleadings. For Novo Nordisk, it preserves all asserted claims under US8114833B2. For Lupin, no dismissal or judgment has been entered, and the infringement challenge continues before a new divisional judge.
US8114833B2 — Liraglutide GLP-1 receptor agonist formulation patent
US8114833B2 is a United States patent held by Novo Nordisk covering liraglutide — a GLP-1 (glucagon-like peptide-1) receptor agonist administered as a recombinant solution injection. Filed under application number US11/435977, the patent relates to formulation or compound aspects of Victoza, commercially available as an 18 mg/3 ml solution (6 mg/ml). Liraglutide was one of the first long-acting GLP-1 analogues approved for type 2 diabetes management, and the patent estate around it represents a critical exclusivity defence for Novo Nordisk.
As the GLP-1 drug class has become commercially dominant — driven by semaglutide but originating with liraglutide — the patent landscape has attracted intense generic challenger activity. US8114833B2 is strategically significant because it potentially covers the injectable formulation of Victoza rather than merely the underlying molecule, making it a barrier to generic bioequivalent entry even where compound patents have expired or narrowed. Companies developing competing liraglutide products or follow-on GLP-1 formulations should assess their exposure to this patent’s claims carefully.
Should your team run an FTO check against US8114833B2?
Any organisation developing, manufacturing, or commercialising a liraglutide-based injectable product — whether a generic, biosimilar, or novel GLP-1 formulation — should assess freedom to operate with respect to US8114833B2. The fact that Novo Nordisk has actively enforced this patent against Lupin, a major generic manufacturer, signals a credible and well-resourced litigation posture. Formulation scientists and regulatory affairs teams working on GLP-1 product development should review the claims before ANDA or BLA submission.
PatSnap Eureka’s FTO Search Agent can map the active claims of US8114833B2 against your product specifications, identify cited prior art, and flag prosecution history estoppel that may limit claim scope. Eureka’s claim monitoring tools can also alert your team to any continuations, divisionals, or related applications in Novo Nordisk’s portfolio that may extend protection beyond the original grant — an essential step for any GLP-1 pipeline product approaching regulatory submission.
Run a freedom-to-operate analysis on US8114833B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman GLP-1 patent infringement cases in New Jersey
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the GLP-1 and liraglutide patent landscape
This Novo Nordisk v. Lupin transfer underscores the competitive pressure building around branded GLP-1 receptor agonist products as generic challengers advance.
Liraglutide is a high-value generic target — expect sustained litigation
Victoza generated billions in annual sales for Novo Nordisk before semaglutide dominated headlines. With the liraglutide composition patents aging, generic filers like Lupin are actively challenging the remaining IP estate. US8114833B2 is likely one of several patents Novo Nordisk is enforcing, suggesting a multi-front litigation strategy typical of Paragraph IV defence.
District of New Jersey remains the dominant Hatch-Waxman battleground
The Camden reassignment keeps this dispute firmly within New Jersey — the preferred jurisdiction for ANDA patent litigation. Companies with generic pipeline products in the GLP-1 space should ensure their IP and regulatory teams are familiar with NJ Local Patent Rules, which impose tight scheduling on claim construction and summary judgment proceedings.
Novo v Lupin — key questions answered
The case was transferred from the Newark Division to the Camden Division of the District of New Jersey on 12 January 2024. It continues under the new docket number 1:23-cv-4027. No merits ruling or settlement has been recorded under the original case number.
The patent asserted is US8114833B2, filed under application US11/435977. It covers aspects of liraglutide, the active ingredient in Novo Nordisk’s Victoza product — a GLP-1 receptor agonist administered as an 18 mg/3 ml recombinant solution injection (6 mg/ml) for type 2 diabetes treatment.
The public record does not specify the reason for the intra-district transfer. In the District of New Jersey, transfers between Newark and Camden divisions typically reflect judicial workload management or consolidation with related Hatch-Waxman litigation before a single judge. The transfer does not reflect any substantive ruling on the merits.
An intra-district transfer is a procedural reassignment with no effect on the substantive claims. All pleadings, parties, and asserted patents carry over. For Hatch-Waxman cases, the 30-month FDA stay (if applicable) continues to run regardless of the transfer, and the generic applicant remains bound by the stay’s expiry timeline.
Novo Nordisk was represented by Fenwick & West LLP and Saul Ewing, LLP, with attorneys including Charles Michael Lizza, William C. Baton, David Feder, Alexander Lee Callo, and Sarah Ann Sullivan. Lupin was represented by Midlige Richter LLC, with James S. Richter as lead counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.